Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutritionals feed Abbott

This article was originally published in The Tan Sheet

Executive Summary

Nutritional sales grew 11 percent in the fourth quarter to $1.28 billion globally, with U.S. revenues climbing nearly 7 percent driven by the launch of infant formula Similac Advanced EarlyShield and continued sales of Glucerna and Ensure. International nutrition sales rose 15 percent, the Abbott Park, Ill.-based firm said Jan. 21. To address increased demand in Asia, where consumers are shaken by the contaminated formula scandal that rocked China in 2008, Abbott will open a manufacturing facility in Singapore this quarter, Investor Relations VP John Thomas said during a same-day earnings call. He also said the firm expects its planned acquisition of Advanced Medical Optics to grow its market share more than $4 billion globally with help from sales of the Tecnis multifocal intraocular lens FDA approved Jan. 16 (1"The Tan Sheet" Jan. 19, 2009, p. 17). Abbott's net sales in the quarter advanced 10.1 percent to $8 billion and for the year revenues grew 13.9 percent to $29.5 billion

You may also be interested in...

Abbott Nutrition Offers Complete Package For Similac Formula Users

Abbott Nutrition's innovative packaging for its Similac line of infant formulas shows the company empathizes with consumer's interests and needs, according to a leading industrial designer

Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts